Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Company Medical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Fineline Cube Apr 21, 2025

Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...

Company Drug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Fineline Cube Apr 21, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...

Company Drug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Fineline Cube Apr 21, 2025

France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...

Company Drug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Fineline Cube Apr 21, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Fineline Cube Apr 21, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Drug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Fineline Cube Apr 21, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...

Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Fineline Cube Apr 21, 2025

hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...

Company Deals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

Fineline Cube Apr 21, 2025

China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...

Company Drug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Fineline Cube Apr 21, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...

Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study

Fineline Cube Apr 21, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

Fineline Cube Apr 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...

Company Drug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

Fineline Cube Apr 21, 2025

China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...

Company Drug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Fineline Cube Apr 21, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...

Company Drug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

Fineline Cube Apr 18, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Fineline Cube Apr 18, 2025

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company Deals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Fineline Cube Apr 18, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...

Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Fineline Cube Apr 18, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...

Company Drug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Fineline Cube Apr 18, 2025

The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...

Posts pagination

1 … 162 163 164 … 653

Recent updates

  • China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.